.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XK02_Niraparib.Niraparib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XK02_Niraparib.Niraparib| name: | Niraparib |
| ATC code: | L01XK02 | route: | oral |
| n-compartments | 2 |
Niraparib is an oral, selective poly(ADP-ribose) polymerase (PARP) inhibitor, primarily used as an anti-cancer agent for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is an approved drug for these indications.
Pharmacokinetic data from adult female ovarian cancer patients after oral administration of niraparib.
Russu, A, et al., & Boulton, M (2025). Population Pharmacokinetics of Niraparib/Abiraterone Acetate Administered as Single-Agent Combination and Dual-Acting Tablets Plus Prednisone for Metastatic Castration-Resistant Prostate Cancer. Advances in therapy 42(4) 1860–1880. DOI:10.1007/s12325-025-03104-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/40016438
Rubinstein, MM, et al., & Makker, V (2021). A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers. Gynecologic oncology 160(1) 71–76. DOI:10.1016/j.ygyno.2020.10.019 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33139041